The Disappointment of the NSABP C-08 Trial

Oncology Times - OncTimes Talk
13/10/2009 9 min
The Disappointment of the NSABP C-08 Trial

Listen "The Disappointment of the NSABP C-08 Trial"

Descargar episodio Ver en sitio original

Episode Synopsis

Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli

More episodes of the podcast Oncology Times - OncTimes Talk

From Ironman to Advocate: Tom Hulsey’s Journey Through Prostate Cancer and Purpose 01/08/2025
Accurate and Actionable: How Oncologists Get Fast, Comprehensive Therapeutic Insights from the OncoExTra® Test 17/07/2025
Empowering Cancer Care Through Movement: A Conversation with Sami Mansfield 01/07/2025
Defying the Odds: Katie Coleman's Journey from Diagnosis to Advocacy 02/06/2025
Making Comprehensive Genomic Profiling More Accurate for Everyone: The Importance of Patient-Matched Tumor-Normal Sequencing 28/05/2025
Transforming colorectal cancer management with tumor informed ctDNA testing 22/05/2025
Lessons in Resilience: Dr. Susan MacDonald's Healthcare Journey 02/05/2025
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities at High Risk 27/03/2025
Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 03/03/2025
Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 03/03/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA